Evidence & concentration worksheet · Immune & Inflammation
LL-37 5 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
LL-37 is a 37-amino-acid peptide produced from the human cathelicidin precursor hCAP-18. It is part of innate immunity and has antimicrobial and immune-signaling activity in laboratory systems. A peptide being naturally present in the body does not make an injected or compounded LL-37 product proven, equivalent, or safe.
Benefits & side effects
A phase IIb double-blind randomized trial studied topical LL-37 with compression therapy in 148 people with hard-to-heal venous leg ulcers. In the full study population, neither LL-37 concentration significantly improved healing versus placebo.[1] Exploratory or subgroup observations cannot replace that prespecified overall result, and this topical wound study does not support injected use, infection treatment, systemic immune claims, or general skin rejuvenation.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Wound Repair and Regeneration — Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers (2021)
- Nature — Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide (2007)
- U.S. FDA — Certain bulk substances that may present significant compounding safety risks (2026)
- U.S. FDA — Understanding the risks of compounded drugs (2026)